Last updated on June 2018

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis


Brief description of study

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.

Clinical Study Identifier: NCT02092467

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Synexus Polska Sp. z o.o. Oddzial w Gdyni
Gdynia, Poland
0.62miles
  Connect »

Pfizer CT.gov Call Center

Centrum medyczne Pratia Gdynia
Gdynia, Poland
0.77miles
  Connect »

Pfizer CT.gov Call Center

Medica Pro Familia Sp. z o.o. S.K.A. Oddzial w Gdynia
Gdynia, Poland
0.77miles
  Connect »

Pfizer CT.gov Call Center

Wojewodzki Zespol Reumatologiczny im. dr Jadwigi Titz-Kosko w Sopocie, Oddzial 1
Sopot, Poland
5.38miles
  Connect »